Our top pick for
Building a portfolio
Lantheus Holdings, Inc is a diagnostics & research business based in the US. Lantheus shares (LNTH) are listed on the NASDAQ and all prices are listed in US Dollars. Lantheus employs 508 staff and has a trailing 12-month revenue of around USD$334.6 million.
|Latest market close||USD$14.78|
|52-week range||USD$8.67 - USD$21.42|
|50-day moving average||USD$12.4293|
|200-day moving average||USD$13.4026|
|Wall St. target price||USD$19.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.008|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-13)||-5.86%|
|1 month (2020-12-23)||-0.34%|
|3 months (2020-10-20)||13.96%|
|6 months (2020-07-20)||-5.50%|
|1 year (2020-01-19)||N/A|
|2 years (2019-01-19)||N/A|
|3 years (2018-01-19)||22.8|
|5 years (2016-01-20)||508.23%|
Valuing Lantheus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Lantheus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Lantheus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1861x. In other words, Lantheus shares trade at around 1861x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Lantheus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.61. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Lantheus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Lantheus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$46.3 million.
The EBITDA is a measure of a Lantheus's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$334.6 million|
|Operating margin TTM||7.93%|
|Gross profit TTM||USD$174.8 million|
|Return on assets TTM||2.59%|
|Return on equity TTM||0.13%|
|Market capitalisation||USD$995.7 million|
TTM: trailing 12 months
There are currently 2.0 million Lantheus shares held short by investors – that's known as Lantheus's "short interest". This figure is 8.4% up from 1.9 million last month.
There are a few different ways that this level of interest in shorting Lantheus shares can be evaluated.
Lantheus's "short interest ratio" (SIR) is the quantity of Lantheus shares currently shorted divided by the average quantity of Lantheus shares traded daily (recently around 461655.60640732). Lantheus's SIR currently stands at 4.37. In other words for every 100,000 Lantheus shares traded daily on the market, roughly 4370 shares are currently held short.
However Lantheus's short interest can also be evaluated against the total number of Lantheus shares, or, against the total number of tradable Lantheus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lantheus's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Lantheus shares in existence, roughly 30 shares are currently held short) or 0.0381% of the tradable shares (for every 100,000 tradable Lantheus shares, roughly 38 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lantheus.
Find out more about how you can short Lantheus stock.
We're not expecting Lantheus to pay a dividend over the next 12 months.
Over the last 12 months, Lantheus's shares have ranged in value from as little as $8.67 up to $21.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lantheus's is 1.3312. This would suggest that Lantheus's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine. The company also offers Xenon, a radiopharmaceutical gas used to assess pulmonary function, and to image cerebral blood flow; Neurolite, an injectable to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable technetium-labeled imaging agent; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium TI 201, which is used in MPI studies to detect cardiovascular disease; Gallium Ga 67 that is used to detect various infections and cancerous tumors; and Quadramet, a therapeutic product. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; and LMI 1195 that is in Phase III clinical trials for the diagnosis and treatment of neuroendocrine tumors. It sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics, and group practices. The company has a strategic collaboration and license agreement with NanoMab Technology Limited to provide an imaging biomarker research tool to pharmaceutical companies and academic centers conducting R&D on PD-L1 immuno-oncology treatments; and strategic collaboration with Insightec Ltd. for the treatment of glioblastoma and neurodegenerative conditions. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.